BioCentury | Jul 3, 2019
Preclinical News
Controlling CAR T toxicity with BMS's Sprycel
...pausing CAR T cell activity. The BCR-ABL tyrosine kinase (BCR-ABL) and Src kinase inhibitor blocks lymphocyte-specific protein tyrosine kinase (LCK)...
...leukemia (ALL) and chronic myelogenous leukemia (CML). Targets: BCR-ABL - BCR-ABL tyrosine kinase; LCK - Lymphocyte-specific protein tyrosine kinase Sandi...
...leukemia (ALL) and chronic myelogenous leukemia (CML). Targets: BCR-ABL - BCR-ABL tyrosine kinase; LCK - Lymphocyte-specific protein tyrosine kinase Sandi...